CN1772108A - 治疗妇女更年期综合症的中西药复方制剂及其制备方法 - Google Patents
治疗妇女更年期综合症的中西药复方制剂及其制备方法 Download PDFInfo
- Publication number
- CN1772108A CN1772108A CN 200510200585 CN200510200585A CN1772108A CN 1772108 A CN1772108 A CN 1772108A CN 200510200585 CN200510200585 CN 200510200585 CN 200510200585 A CN200510200585 A CN 200510200585A CN 1772108 A CN1772108 A CN 1772108A
- Authority
- CN
- China
- Prior art keywords
- extractum
- vitamin
- weight portions
- preparation
- radix rehmanniae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 25
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 83
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 80
- 241001533104 Tribulus terrestris Species 0.000 claims abstract description 63
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 63
- 238000002360 preparation method Methods 0.000 claims abstract description 57
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 40
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 40
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 40
- 239000011709 vitamin E Substances 0.000 claims abstract description 40
- 229940046009 vitamin E Drugs 0.000 claims abstract description 40
- 239000007901 soft capsule Substances 0.000 claims abstract description 17
- 239000003826 tablet Substances 0.000 claims abstract description 15
- 239000002775 capsule Substances 0.000 claims abstract description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract 22
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract 11
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract 11
- 229960003495 thiamine Drugs 0.000 claims abstract 11
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract 11
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract 11
- 239000011691 vitamin B1 Substances 0.000 claims abstract 11
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract 11
- 239000011726 vitamin B6 Substances 0.000 claims abstract 11
- 229940011671 vitamin b6 Drugs 0.000 claims abstract 11
- 239000000843 powder Substances 0.000 claims description 84
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 73
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 71
- 238000001035 drying Methods 0.000 claims description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 235000020958 biotin Nutrition 0.000 claims description 41
- 239000011616 biotin Substances 0.000 claims description 41
- 229960002685 biotin Drugs 0.000 claims description 41
- 238000002156 mixing Methods 0.000 claims description 41
- 229960003080 taurine Drugs 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 35
- 108010010803 Gelatin Proteins 0.000 claims description 34
- 239000008273 gelatin Substances 0.000 claims description 34
- 229920000159 gelatin Polymers 0.000 claims description 34
- 235000019322 gelatine Nutrition 0.000 claims description 34
- 235000011852 gelatine desserts Nutrition 0.000 claims description 34
- 235000011187 glycerol Nutrition 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 28
- 239000006187 pill Substances 0.000 claims description 28
- 206010013786 Dry skin Diseases 0.000 claims description 26
- 239000008187 granular material Substances 0.000 claims description 25
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000000758 substrate Substances 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000003292 glue Substances 0.000 claims description 16
- 238000000465 moulding Methods 0.000 claims description 16
- 239000007779 soft material Substances 0.000 claims description 16
- 239000007919 dispersible tablet Substances 0.000 claims description 15
- 235000012424 soybean oil Nutrition 0.000 claims description 15
- 239000003549 soybean oil Substances 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 12
- 238000005469 granulation Methods 0.000 claims description 12
- 230000003179 granulation Effects 0.000 claims description 12
- 239000008188 pellet Substances 0.000 claims description 12
- 239000004408 titanium dioxide Substances 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 238000004513 sizing Methods 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 238000005096 rolling process Methods 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 239000002826 coolant Substances 0.000 claims description 6
- 229960004793 sucrose Drugs 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 239000008118 PEG 6000 Substances 0.000 claims description 5
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 5
- 239000002390 adhesive tape Substances 0.000 claims description 5
- 235000010357 aspartame Nutrition 0.000 claims description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 5
- 229940008099 dimethicone Drugs 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- 238000007664 blowing Methods 0.000 claims description 4
- 230000036760 body temperature Effects 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 4
- 206010022437 insomnia Diseases 0.000 abstract description 4
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000031091 Amnestic disease Diseases 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 208000008454 Hyperhidrosis Diseases 0.000 abstract 1
- 241000735234 Ligustrum Species 0.000 abstract 1
- 206010027304 Menopausal symptoms Diseases 0.000 abstract 1
- 206010033557 Palpitations Diseases 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 229930003756 Vitamin B7 Natural products 0.000 abstract 1
- 230000006986 amnesia Effects 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 230000037315 hyperhidrosis Effects 0.000 abstract 1
- 235000011912 vitamin B7 Nutrition 0.000 abstract 1
- 239000011735 vitamin B7 Substances 0.000 abstract 1
- 229930003270 Vitamin B Natural products 0.000 description 39
- 235000019156 vitamin B Nutrition 0.000 description 39
- 239000011720 vitamin B Substances 0.000 description 39
- 235000019441 ethanol Nutrition 0.000 description 23
- 239000000047 product Substances 0.000 description 16
- -1 micropill Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 10
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical group C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 9
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 9
- 238000012216 screening Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 235000010489 acacia gum Nutrition 0.000 description 7
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 7
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003605 opacifier Substances 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000703 high-speed centrifugation Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000008717 functional decline Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
种类 | 蔗糖 | 阿司帕坦 | 甜蜜素 |
甜度味质价格用量安全性 | 1好1不受限制好 | 150-300倍好80倍不受限制好 | 50倍有类似金属味成本低用量受限,一般不超过0.1%较好 成本低较好 |
样品 | 纯药粉 | 药粉十糊精 |
称瓶编号物料重量(g)间隔时间 | 11.0021吸湿百分率(%) | 20.9982 |
1h2h3h4h6h8h10h12h24h36h48h | 2.445.326.488.510.2112.4516.5418.7422.5527.3232.41 | 1.142.544.215.446.788.419.6811.7413.2516.1719.36 |
处方 | CMC-Na | PVPK30(%) | |
123 | 内加(A)1.5%2.0%2.5% | 外加(B)2.5%3.0%3.5% | C01.01.5 |
组别 | 1(A) | 2(B) | 3(C) | 4(D) | 崩解时限(sec) |
本发明处方1本发明处方2本发明处方3 | 111 | 123 | 123 | 123 | 234210170 |
本发明处方4本发明处方5本发明处方6本发明处方7本发明处方8本发明处方9 | 222333 | 123123 | 231312 | 312231 | 22016512018011080 |
样品 | 纯药粉 | 药粉+淀粉 |
称瓶编号物料重量(g) | 11.015 | 20.995 |
时间 | 吸湿百分率(%) | |
1h2h4h8h12h24h48h72h | 1.745.478.4111.4618.4721.7432.4641.32 | 1.132.476.5410.3513.4217.1321.4227.96 |
试验号 | 乙醇浓度 | 制软材情况 |
123 | 70%乙醇65%乙醇50%乙醇 | 软材易粘结软材适中软材粘度不够 |
试验号 | 大豆油用量(占总重量的比例) | 制丸情况 |
123 | 65%乙醇、1%大豆油65%乙醇、1.2%大豆油65%乙醇、1.5%大豆油 | 软材粘度不够,无法制丸软材适中,适宜制丸软材易粘结,制丸困难 |
编号 | 包衣锅转速(r/min) | 溶散时间(min) | 成型性 |
1 | 30 | 5.68 | 较差 |
2 | 40 | 6.42 | 较好 |
3 | 50 | 11.47 | 较硬 |
4 | 70 | 13.24 | 坚硬 |
5 | 100 | 16.12 | 坚硬 |
药物量(g)∶基质量(g) | 1∶1 | 1∶1.2 | 1∶1.5 |
药液质量 | 粘度大、流动性差 | 粘度、流动性均好 | 粘度差,流动性大 |
配方 | 粘度(mpa·s) | 柔软性 | 弹性 | 韧性 | 特点 | 综合评价 |
1.明胶100g∶甘油35g∶水100g2.明胶100g∶甘油45g∶水100g3.明胶100g∶甘油55g∶水100g4.明胶100g∶甘油45g∶水80g5.明胶100g∶甘油45g∶水120g6.明胶100g∶甘油35g∶山梨醇5g∶水100g7.明胶100g∶甘油35g∶山梨醇10g∶水100g8.明胶100g∶甘油45g∶山梨醇5g∶水100g | 3.623.323.593.733.113.433.463.52 | -+++++++-+++ | -++++++++++ | ++++++-++++ | 脆,硬韧、成膜性弹性好弹性好,粘度大太软韧刺穿性能好韧 | 差很好一般很好差较好很好较好 |
9.明胶100g∶甘油45g∶山梨醇10g∶水100g10.明胶100g∶甘油25g∶山梨醇10g∶水100g11.明胶100g∶甘油35g∶山梨醇20g∶水100g12.明胶100g∶甘油55g∶山梨醇5g∶水90g | 3.473.623.573.36 | ++++ | ++++++ | -++++ | 软韧刺穿性能好0.5mm以下胶皮易拉断 | 一般较好很好较好 |
13.明胶84g∶甘油28g∶山梨醇28g∶水20g | 胶液太稠,无法化胶 | |||||
14.明胶100g∶阿拉伯胶25g∶甘油35g∶水100g15.明胶85g∶阿拉伯胶15g∶甘油45g∶水100g16.明胶85g∶阿拉伯胶15g∶甘油60g∶山梨醇10g∶水60g17.明胶50g∶阿拉伯胶150g∶山梨醇10g∶甘油60g∶水55g18.明胶85g∶阿拉伯胶15g∶甘油45g∶山梨醇10g∶水110g19.明胶85g∶阿拉伯胶15g∶甘油60g∶山梨醇10g∶水90g20.明胶100g∶阿拉伯胶25g∶甘油45g∶山梨醇5g∶水100g | 3.573.513.393.683.523.383.35 | --+++++ | -++-++- | ++++-+++ | 颜色偏灰脆0.2~0.8mm胶皮撕裂强度大脆脆 颜色偏灰0.85mm以下胶皮弹性差颜色偏灰 | 差差很好差一般一般一般 |
用量比例 | 胶皮透明度 | 胶浆粘度(Mpa·S) | 综合评价 |
明胶100g∶甘油45g∶水100g∶二氧化钛0.5g明胶100g∶甘油45g∶水100g∶二氧化钛1g明胶100g∶甘油45g∶水100g∶二氧化钛2g明胶100g∶甘油45g∶水100g∶二氧化钛3g | 半透明半透明半透明不透明 | 3.123.193.363.52 | 用量不够用量不够好粘度较大 |
粒度 | 60目 | 80目 | 100目 | 120目 |
混匀情况 | 不能混匀,高速离心(10000/min)30min分层 | 能混匀,高速离心(10000/min)30min不分层 | 能混匀,高速离心(10000/min)30min不分层 | 能混匀,高速离心(10000/min)30min不分层 |
温度(℃) | 化胶时间(H) | 胶皮质量 |
5060708090 | 65554 | 好好好好较硬 |
处方号 | 处方1 | 处方2 | 处方3 | 处方4 | 处方5 |
药物(份)聚乙二醇6000(份)聚乙二醇10000(份) | 1030- | 1020- | 10205 | 102010 | 101020 |
主药与基质的融合情况体系流动性滴丸外观滴丸硬度丸重差异溶散时限(min) | 主药能与基质融合体系流动性差圆整度较好硬度小15%7~8 | 主药能与基质融合体系流动性差圆整度差差20%4~5 | 主药能与基质融合体系流动性好圆整度好硬度好7.5%9~10 | 主药能与基质融合体系流动性好稍有拖尾硬度好10%13~15 | 主药能与基质融合体系流动性较好有拖尾硬度好12%13~15 |
组别 | 温度/℃ | 滴距/cm | 冷却液高度/cm | 丸重合格率/% |
123456789 | 909090808080707070 | 458458458 | 506070607050705060 | 65.283.285.192.394.791.292.188.684.3 |
组别 | 治疗前 | 治疗后 | |||
第1周 | 第2周 | 第4周 | 第6周 | ||
本发明组 | 34.82±9.36 | 29.23±8.42* | 23.87±9.17* | 17.68±8.32* | 12.75±7.13* |
氯丙咪嗪组 | 35.16±10.14 | 32.65±9.77 | 24.32±9.72* | 18.14±8.64* | 13.14±7.42* |
组别 | 治疗前 | 治疗后 | |||
第1周 | 第2周 | 第4周 | 第6周 | ||
本发明组 | 23.12±9.31 | 18.14±7.21* | 14.31±7.62* | 11.52±6.30* | 8.63±6.46* |
氯丙咪嗪组 | 23.92±8.73 | 19.12±8.05* | 15.16±8.01* | 11.63±6.71* | 9.02±6.54* |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005102005852A CN100374132C (zh) | 2005-10-08 | 2005-10-08 | 治疗妇女更年期综合症的中西药复方制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005102005852A CN100374132C (zh) | 2005-10-08 | 2005-10-08 | 治疗妇女更年期综合症的中西药复方制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1772108A true CN1772108A (zh) | 2006-05-17 |
CN100374132C CN100374132C (zh) | 2008-03-12 |
Family
ID=36759359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005102005852A Expired - Fee Related CN100374132C (zh) | 2005-10-08 | 2005-10-08 | 治疗妇女更年期综合症的中西药复方制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100374132C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8092841B2 (en) * | 2007-08-08 | 2012-01-10 | Bionovo, Inc. | Estrogenic extracts of Ligustrum lucidum ait. of the oleaceae family and uses thereof |
CN105769879A (zh) * | 2016-03-15 | 2016-07-20 | 山东仁和堂药业有限公司 | 一种用于镇静助眠的药物制剂及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100344308C (zh) * | 2003-04-28 | 2007-10-24 | 浙江大学药业有限公司 | 一种抗衰老及免疫调节的药用组合物 |
CN1634264A (zh) * | 2004-11-03 | 2005-07-06 | 贵州海泰药业技术有限公司 | 更年灵软胶囊的制备方法 |
-
2005
- 2005-10-08 CN CNB2005102005852A patent/CN100374132C/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8092841B2 (en) * | 2007-08-08 | 2012-01-10 | Bionovo, Inc. | Estrogenic extracts of Ligustrum lucidum ait. of the oleaceae family and uses thereof |
CN105769879A (zh) * | 2016-03-15 | 2016-07-20 | 山东仁和堂药业有限公司 | 一种用于镇静助眠的药物制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100374132C (zh) | 2008-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1762400A (zh) | 血塞通制剂及其制备方法 | |
CN1316990C (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1768800A (zh) | 治疗淋病、泌尿系统感染的中药制剂及其制备方法 | |
CN1772108A (zh) | 治疗妇女更年期综合症的中西药复方制剂及其制备方法 | |
CN100496496C (zh) | 治疗2型糖尿病的复方二甲双胍格列吡嗪制剂及其制备方法 | |
CN1883537A (zh) | 治疗高血压、高血脂的中药复方制剂及其制备方法 | |
CN1883674A (zh) | 治疗糖尿病的降糖宁制剂及其制备方法 | |
CN1853660A (zh) | 灯盏细辛制剂及其制备方法 | |
CN1628764A (zh) | 穿心莲制剂及其制备方法 | |
CN1443535A (zh) | 马来酸替加色罗口服制剂及其制备工艺——治疗肠易惹综合征 | |
CN1733109A (zh) | 治疗冠心病的软胶囊及其制备方法 | |
CN1850253A (zh) | 千金保孕制剂及新的制备方法 | |
CN1772234A (zh) | 治疗妇科疾病的中药制剂及其制备方法 | |
CN1698597A (zh) | 丹参酮ⅱa滴丸及其制备方法和应用 | |
CN1853670A (zh) | 冠心丹参微丸制剂及其制备方法 | |
CN1771940A (zh) | 抗溃疡的西药制剂及其制备方法 | |
CN1771970A (zh) | 治疗呼吸道疾病的西药复方制剂及其制备方法 | |
CN101890057A (zh) | 治疗胃肠道、泌尿道感染及心、脑血管疾病用的凤尾草制剂及其制备方法 | |
CN1850241A (zh) | 维c银翘分散片及其制备方法 | |
CN1768794A (zh) | 治疗呼吸道系统疾病的中药制剂及其制备方法 | |
CN1981854A (zh) | 七味红花殊胜口服胶囊剂、片剂及其制备方法 | |
CN1698664A (zh) | 板蓝根泡腾片及制备方法 | |
CN1733272A (zh) | 治疗泌尿系统等疾病的三金药物制剂及其制备方法 | |
CN102058869B (zh) | 一种木香顺气胃漂浮制剂及其制备方法 | |
CN1813886B (zh) | 用于活血化瘀、通脉止痛的银盏心脉中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENQI PHAMACEUTICAL CO LTD, GUIZHOU Free format text: FORMER OWNER: GUIZHOU SHENQI GROUP HOLDING CO., LTD. Effective date: 20120327 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120327 Address after: 550004 Guizhou Province, Guiyang city Beijing Road No. 1 Patentee after: GUIZHOU SHENQI PHARMACEUTICAL Co.,Ltd. Address before: 550004 Guizhou Province, Guiyang city Beijing Road No. 1 Patentee before: GUIZHOU MAOJKA GROUP HOLDING Co.,Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: GUIZHOU SHENQI PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHENQI PHAMACEUTICAL CO LTD, GUIZHOU |
|
CP01 | Change in the name or title of a patent holder |
Address after: 550004 Guizhou Province, Guiyang city Beijing Road No. 1 Patentee after: GUIZHOU SHENQI PHARMACEUTICAL Co.,Ltd. Address before: 550004 Guizhou Province, Guiyang city Beijing Road No. 1 Patentee before: GUIZHOU SHENQI PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080312 |